Work

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Year: 2020

Type: article

Study design: Clinical Trial

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(20)30354-9

Authors: Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Fredette Hita, Jason Valent, Michael Rosenzweig, Jeffrey A Zonder, Madhav Dhodapkar, Natalie Callander, Todd Zimmerman, Peter M Voorhees, Brian Durie, S Vincent Rajkumar, Paul G Richardson, Robert Z Orlowski

Institutions: Levine Cancer Institute, Cancer Research And Biostatistics, Mayo Clinic in Florida, University of Rochester Medicine, University of Rochester, Cleveland Clinic, City Of Hope National Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Emory University, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Chicago, Cedars-Sinai Medical Center, Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Leukemia and Lymphoma Society, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Celgene, National Institutes of Health, University of Texas MD Anderson Cancer Center, National Cancer Institute

Awards: G1545560008, G1548551769, ECOG-ACRIN Network Group Operations Center, G1938688226, G1940029228, G2953001543, G3468546125, G557084418, Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma, National Clinical Trials Network Research at the University of Wisconsin, G8842964906

OpenAlex ID: W3113412439

FWCI: 10.08

Cites: 35

Cited by: 126

Related to: 10